In the ARK1 model, mice treated with bevacizumab plus AVB-500 had significantly fewer resectable tumor nodules (over 1 mm) than mice treated with AVB-500 alone or bevacizumab alone (4.7 vs. 8.4, p = 0.0245; 4.7 vs. 9.0, p < 0.0001, Figure 4B). The gene discussed is AURKA; the disease is neoplasm.